Jaguar Health Seeks Shareholder Nod for Key Equity Issuances

TL;DR

**JAGX needs these equity issuance approvals to stay listed and funded, or it's going to be a rough ride for shareholders.**

AI Summary

Jaguar Health, Inc. (JAGX) is convening a Special Meeting of Stockholders on December 8, 2025, to seek approval for two critical proposals under Nasdaq Listing Rule 5635(d). The first proposal involves the issuance of Common Stock upon the exchange of Series N Perpetual Preferred Stock, par value $0.0001 per share, previously issued to accredited investors. The second proposal seeks approval for the issuance of New PIPE Shares and a Pre-Funded PIPE Warrant, collectively termed "New PIPE Securities," stemming from a securities purchase agreement dated September 28, 2025. These approvals are crucial for Jaguar Health to maintain compliance with Nasdaq listing requirements, as the issuance of these securities could exceed 20% of the company's outstanding common stock or voting power. Failure to secure stockholder approval could lead to delisting concerns and impact future financing capabilities. The company also seeks approval for potential adjournments to solicit additional proxies if initial votes are insufficient. As of October 31, 2025, there were 3,735,835 shares of voting common stock, 121.3822 shares of Series L Preferred Stock, 260 shares of Series M Preferred Stock, and 950.8 shares of Series N Preferred Stock outstanding.

Why It Matters

This DEF 14A filing is critical for Jaguar Health's financial stability and market standing. Approving the issuance of Common Stock from Series N Preferred Stock and the New PIPE Securities ensures the company can complete its financing arrangements and remain compliant with Nasdaq Listing Rule 5635(d). For investors, a 'FOR' vote mitigates the risk of delisting and signals a path for continued operations, while a 'NO' vote could trigger significant uncertainty and potentially impair the company's ability to raise capital, impacting its competitive position in the biopharmaceutical sector. Employees and customers benefit from a stable, well-funded company, whereas a failure to secure these approvals could lead to operational disruptions and a loss of market confidence.

Risk Assessment

Risk Level: high — The risk level is high because both Proposal 1 and Proposal 2 are non-routine matters requiring stockholder approval under Nasdaq Listing Rule 5635(d). Failure to obtain these approvals could lead to non-compliance with Nasdaq rules, potentially resulting in delisting. The Series N Preferred Stock holders are explicitly not eligible to vote for Proposal 1, which could make securing the necessary majority more challenging for the remaining voting shareholders.

Analyst Insight

Investors should carefully review the implications of these equity issuances on their ownership stake and the company's capital structure. Voting 'FOR' Proposals 1 and 2 is crucial to support Jaguar Health's continued Nasdaq listing and access to capital, which is vital for its long-term viability. Consider contacting Georgeson LLC at 866-821-0284 for assistance with voting.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• 3,735,835 — Shares of voting common stock outstanding (As of October 31, 2025, the Record Date)
• 121.3822 — Shares of Series L Perpetual Preferred Stock outstanding (As of October 31, 2025, each with 3,787 votes)
• 260 — Shares of Series M Perpetual Preferred Stock outstanding (As of October 31, 2025, each with 10,000 votes)
• 950.8 — Shares of Series N Perpetual Preferred Stock outstanding (As of October 31, 2025, each with 1,428 votes)
• $0.0001 — Par value per share (Applicable to Common Stock, Series L, M, and N Preferred Stock)
• 9.99% — Voting Cap for Series L and M Preferred Stock (Maximum voting power for holders of Series L and M Preferred Stock)
• 19.99% — Voting Cap for Series N Preferred Stock (Maximum voting power for holders of Series N Preferred Stock)
• 1/3 — Quorum requirement (Fraction of voting power required for a quorum at the Special Meeting)
• $7,500 — Base fee for proxy solicitor (Fee paid to Georgeson LLC for proxy solicitation services)
• December 8, 2025 — Date of Special Meeting (Stockholders will vote on proposals on this date)

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant filing the DEF 14A
• Nasdaq (regulator) — Exchange requiring stockholder approval under Rule 5635(d)
• Lisa A. Conte (person) — Chief Executive Officer & President of Jaguar Health, Inc.
• Georgeson LLC (company) — Proxy solicitor for Jaguar Health, Inc.
• Equiniti Trust Company, LLC (company) — Transfer Agent for Jaguar Health, Inc.
• Jonathan S. Wolin (person) — Secretary of Jaguar Health, Inc.
• United States Securities and Exchange Commission (regulator) — Regulatory body overseeing the filing
• 200 Pine Street, Suite 400, San Francisco, CA 94104 (location) — Location of the Special Meeting and company headquarters
• September 28, 2025 (date) — Date of the New PIPE Purchase Agreement
• October 31, 2025 (date) — Record Date for the Special Meeting

FAQ

Industry Context

Jaguar Health operates in the biopharmaceutical sector, focusing on developing and commercializing novel, plant-based prescription medicines for specific niche markets. The industry is characterized by high R&D costs, long development cycles, stringent regulatory hurdles from bodies like the FDA, and significant competition from both established pharmaceutical companies and emerging biotech firms. Success often hinges on clinical trial outcomes, intellectual property protection, and effective market access strategies.

Regulatory Implications

The primary regulatory implication for Jaguar Health in this filing is the need to comply with Nasdaq Listing Rule 5635(d). Failure to obtain stockholder approval for the proposed securities issuances could result in the company exceeding the 20% threshold for share dilution without proper authorization, potentially leading to delisting from the Nasdaq Stock Market. Maintaining Nasdaq compliance is crucial for liquidity and future capital raising.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-12-08: Special Meeting of Stockholders — Stockholders will vote on critical proposals related to the issuance of Common Stock and New PIPE Securities, which are necessary for Nasdaq compliance.
• 2025-10-31: Record Date for Special Meeting — Established the cutoff for determining which stockholders are eligible to vote at the Special Meeting.
• 2025-09-28: Securities Purchase Agreement — This agreement led to the issuance of New PIPE Securities, requiring stockholder approval for their issuance under Nasdaq rules.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual meeting of shareholders, including proxy materials and proposals to be voted on. (This document contains the critical proposals and information Jaguar Health needs to present to its stockholders for approval.)

Nasdaq Listing Rule 5635(d)

A rule requiring shareholder approval for certain issuances of securities that could result in a substantial dilution of existing shareholders' ownership or voting power, typically exceeding 20%. (Jaguar Health requires stockholder approval under this rule because the proposed issuances of Common Stock and New PIPE Securities may exceed the 20% threshold.)

Series N Perpetual Preferred Stock

A class of preferred stock that has no maturity date and pays a fixed dividend. It was issued to accredited investors and is convertible into common stock. (The exchange of this preferred stock for common stock is one of the key proposals requiring stockholder approval.)

New PIPE Securities

Securities issued in a Private Investment in Public Equity (PIPE) transaction, which typically involves selling stock or warrants to institutional investors. In this case, it includes New PIPE Shares and a Pre-Funded PIPE Warrant. (The issuance of these securities is the second critical proposal requiring stockholder approval to maintain Nasdaq compliance.)

Accredited Investors

Investors who meet certain income or net worth requirements and are therefore presumed by the SEC to be able to bear the risk of investing in securities that are not registered with the SEC. (The Series N Perpetual Preferred Stock was issued to these types of investors, indicating a private placement transaction.)

Proxy

A document or instruction authorizing another person to act as one's agent or vote on one's behalf, especially in a shareholder meeting. (The company is soliciting proxies to ensure sufficient votes are cast to approve the proposals at the Special Meeting.)

Year-Over-Year Comparison

This filing focuses on an upcoming Special Meeting and specific proposals related to securities issuance and Nasdaq compliance, rather than a comprehensive review of past performance. Therefore, direct year-over-year comparisons of financial metrics like revenue growth or margin changes are not applicable within this DEF 14A context. The key comparison is to the company's ongoing need to manage its capital structure and maintain its stock exchange listing, highlighting the critical nature of these upcoming votes.

Key Financial Figures

• $0.0001 — N Perpetual Preferred Stock, par value $0.0001 per share (the "Series N Preferred Stoc
• $7,500 — LC to solicit proxies for a base fee of $7,500 plus reimbursement of reasonable out-of

Filing Documents

• d32840ddef14a.htm (DEF 14A) — 214KB
• g32840dsp001.jpg (GRAPHIC) — 116KB
• g32840dsp002.jpg (GRAPHIC) — 158KB
• g32840g01a01.jpg (GRAPHIC) — 54KB
• g32840g01a02.jpg (GRAPHIC) — 46KB
• g32840g01a03.jpg (GRAPHIC) — 38KB
• 0001193125-25-274382.txt ( ) — 1426KB
• jagx-20241231.xsd (EX-101.SCH) — 2KB
• d32840ddef14a_htm.xml (XML) — 1KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth information regarding the beneficial ownership of shares of our Common Stock, Series L Preferred Stock, Series M Preferred Stock and Series N Preferred Stock as of October 31, 2025 for: each person known to us to be the beneficial owner of more than 5% of our outstanding shares of Common Stock, Series L Preferred Stock, Series M Preferred Stock and Series N Preferred Stock; each of our named executive officers; each of our directors; and all directors and named executive officers as a group. Information with respect to beneficial ownership has been furnished by each director, executive officer or beneficial owner of more than 5% of our Common Stock, Series L Preferred Stock, Series M Preferred Stock and Series N Preferred Stock. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting and investment power with respect to the securities. Except as otherwise provided by footnote, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of Common Stock, Series L Preferred Stock, Series M Preferred Stock and Series N Preferred Stock shown as beneficially owned by them. The number of shares of Common Stock used to calculate the percentage ownership of each listed person includes the shares of Common Stock underlying options, warrants or convertible securities held by such persons that are currently exercisable or convertible within 60 days of October 31, 2025, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Percentage of beneficial ownership of Common Stock is based on 3,735,835 shares of Common Stock outstanding as of October 31, 2025. Percentage beneficial ownership of Series L Preferred Stock is based on 121.3822 shares of Series L Preferred Stock outstanding as of